Clinical trials: Semaglutide
- Drug or intervention Semaglutide
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Metabolism and Nutrition Disorder, Obesity
Investigation of Safety and Efficacy of Once-daily Semaglutide in Obese Subjects Without Diabetes Mellitus
This trial is conducted globally. The aim of this trial is to investigate safety and efficacy of once-daily semaglutide in obese subjects without diabetes mellitus.
- Trial name
- NCT02453711
- Testing
- semaglutide, liraglutide
- Where
- 74 sites in United States, Australia and 6 more
- Volunteers
- 957 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM)
This is a study for participants with type 2 diabetes mellitus. The main purpose of this study is to learn more about how tirzepatide, semaglutide and placebo affect the body's ability to respond to blood sugar levels after a…
- Trial name
- NCT03951753
- Testing
- Tirzepatide, Semaglutide
- Where
- 2 sites in Germany
- Volunteers
- 117 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes
The reason for this study is to compare the effect of the study drug tirzepatide to semaglutide on blood sugar levels in participants with type 2 diabetes.
- Trial name
- SURPASS-2 (NCT03987919)
- Testing
- Tirzepatide, Semaglutide
- Where
- 127 sites in United States, Argentina and 7 more
- Volunteers
- 1,879 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes
This trial is conducted globally. The aim of the trial is to investigate efficacy and long-term safety of oral semaglutide versus sitagliptin in subjects with type 2 diabetes.
- Trial name
- PIONEER 3 (NCT02607865)
- Testing
- semaglutide, sitagliptin
- Where
- 242 sites in United States, Argentina and 13 more
- Volunteers
- 1,864 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in People Who Have a Body Weight Above the Healthy Range
This study will look how well semaglutide tablets taken once daily helps people with body weight above the healthy range. Participants will either get semaglutide 25 milligram (mg) once daily or placebo once daily.
- Trial name
- OASIS 4 (NCT05564117)
- Testing
- Semaglutide
- Where
- 23 sites in United States, Canada and 2 more
- Volunteers
- 307 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program
This study will look at the change in participant's body weight from the start to the end of the study. This is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy"…
- Trial name
- STEP 3 (NCT03611582)
- Testing
- Semaglutide
- Where
- 41 sites in United States
- Volunteers
- 611 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)
This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to semaglutide taken once a week in people with type 2 diabetes.
- Trial name
- COMBINE 2 (NCT05259033)
- Testing
- IcoSema, Semaglutide 1 mg
- Where
- 193 sites in United States, Brazil and 13 more
- Volunteers
- 683 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes
The researchers are doing this study to look whether the type 2 diabetes medicine, semaglutide, has a positive effect on heart disease.
- Trial name
- SOUL (NCT03914326)
- Testing
- Semaglutide
- Where
- 492 sites in United States, Algeria and 32 more
- Volunteers
- 9,651 people
- Sponsor
- Novo Nordisk A/S
Obesity
A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range
Two different groups of healthy volunteers will be chronically treated with GLP-1 drugs PF-07081532 or alternatively Semaglutide.
- Trial name
- NCT05671653
- Testing
- PF-07081532, Semaglutide
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2
A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes
This study compares the effect of two doses of semaglutide (1.0 mg and 2.0 mg) in people with type 2 diabetes (T2D). People taking part in the study will take the medicine together with their current diabetes medicine…
- Trial name
- SUSTAIN FORTE (NCT03989232)
- Testing
- Semaglutide
- Where
- 129 sites in United States, Bulgaria and 9 more
- Volunteers
- 961 people
- Sponsor
- Novo Nordisk A/S
Obesity
Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity
This study evaluated the safety of VTX3232 administered alone or in combination with semaglutide in participants with obesity. Approximately 160 participants were randomized to receive VTX3232 30 mg, placebo, VTX3232 30 mg in…
- Trial name
- NCT06771115
- Testing
- VTX3232 30 mg, VTX3232 30 mg in combination with semaglutide
- Where
- 14 sites in United States
- Volunteers
- 175 people
- Sponsor
- Zomagen Biosciences Ltd.
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.
This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to investigate efficacy and safety of semaglutide versus dulaglutide as add-on to metformin in subjects with type 2 diabetes.
- Trial name
- SUSTAIN 7 (NCT02648204)
- Testing
- semaglutide, Dulaglutide
- Where
- 209 sites in United States, Bulgaria and 15 more
- Volunteers
- 1,201 people
- Sponsor
- Novo Nordisk A/S
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)
The principal goal of this study is to determine the efficacy of efinopegdutide in liver fat reduction in participants with NAFLD.
- Trial name
- NCT04944992
- Testing
- Efinopegdutide 20 mg/mL, Semaglutide 1.34 mg/mL
- Where
- 69 sites in United States, Argentina and 14 more
- Volunteers
- 145 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 Diabetes
This study looks at how well a new medicine called cagrilintide works together with semaglutide on blood sugar levels in people with type 2 diabetes compared to cagrilintide alone or semaglutide alone.
- Trial name
- NCT04982575
- Testing
- Semaglutide 2.4 mg, Cagrilintide 2.4 mg
- Where
- 23 sites in United States
- Volunteers
- 92 people
- Sponsor
- Novo Nordisk A/S
Nonalcoholic Steatohepatitis
Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)
The primary objective of this study is to evaluate the safety and tolerability of study drug(s) in participants with nonalcoholic steatohepatitis (NASH).
- Trial name
- NCT03987074
- Testing
- Semaglutide, Firsocostat, Cilofexor
- Where
- 18 sites in United States
- Volunteers
- 109 people
- Sponsor
- Gilead Sciences
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus
This trial is conducted globally. The aim of this trial is to investigate Efficacy and Safety of Oral Semaglutide versus Empagliflozin in Subjects with Type 2 Diabetes Mellitus.
- Trial name
- PIONEER 2 (NCT02863328)
- Testing
- semaglutide, empagliflozin
- Where
- 106 sites in United States, Argentina and 10 more
- Volunteers
- 822 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial
The main purpose of this study is to compare the effects of semaglutide (Ozempic®) with the effects of other treatments for type 2 diabetes in a normal practice setting.
- Trial name
- NCT03596450
- Testing
- Semaglutide, Standard of care
- Where
- 181 sites in United States, Canada
- Volunteers
- 1,278 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range
This study will look at how the investigational dose of semaglutide works in helping people with excess body weight, to lose weight.
- Trial name
- STEP12 (NCT06041217)
- Testing
- Semaglutide
- Where
- 21 sites in China, Taiwan
- Volunteers
- 242 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2, Chronic Kidney Disease
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
We are doing this study to learn more about how semaglutide may help fight chronic kidney disease in people with type 2 diabetes. We are doing this by looking into how semaglutide works in the kidneys.
- Trial name
- REMODEL (NCT04865770)
- Testing
- Semaglutide
- Where
- 49 sites in United States, Canada and 6 more
- Volunteers
- 106 people
- Sponsor
- Novo Nordisk A/S
Nonalcoholic Steatohepatitis
Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
The goal of this clinical study is to understand whether the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firsocostat (CILO/FIR), cause fibrosis improvement and Nonalcoholic Steatohepatitis…
- Trial name
- WAYFIND (NCT04971785)
- Testing
- Semaglutide (SEMA), Cilofexor (CILO)/Firsocostat (FIR), PTM SEMA
- Where
- 242 sites in United States, Australia and 5 more
- Volunteers
- 457 people
- Sponsor
- Gilead Sciences